科前生物(688526)
 
 
  日线
顶尖财经网欢迎您!
  K线
 
 最新动态
  投资评级

研究机构 评级日期 最新评级 上次评级
西部证券 2024-04-29 买入
兴业证券 2024-04-11 增持
国投证券 2024-04-09 买入
西南证券 2024-04-09 买入
东兴证券 2024-04-08 买入
国信证券 2024-04-08 买入
  盈利预测
据科前生物一季报分析:

  盈利能力维持稳定,主营获利能力有较大削弱

  成长能力明显恶化,公司规模由扩张变为收缩

  偿债能力有所加强,即时支付现金能力明显加强

  运营能力维持稳定,中长期融资能力得到很大提升

  现金流能力有所削弱,可持续经营能力转向恶化

  财务数据
    截至2024年第一季度实现净利润0.87亿元,每股收益0.18元。

    截至2024年第一季度最新股东权益390367.90万元,未分配利润202193.77万元。

    截至2024年第一季度最新总资产461838.41万元,负债71470.51万元。

利润表
报告期2024-03-312023-12-312023-09-302023-06-30
营业总收入204,929,240.41,064,074,588.89827,439,173.94531,839,356.71
营业总成本117,548,562.59547,826,665.17407,570,296.65263,731,462.07
营业利润100,624,673.5459,131,690.91412,743,443.37276,689,466.17
利润总额100,009,570.54457,580,664.5411,654,477.45275,005,589.86
净利润87,075,680.66395,580,552.7357,180,085.48238,976,717.5
其他综合收益3,322,297.4725,333,622.92--
综合收益总额90,397,978.13420,914,175.62357,180,085.48238,976,717.5
资产负债表
报告期2024-03-312023-12-312023-09-302023-06-30
流动资产合计2,472,776,254.392,566,086,573.762,973,386,605.592,794,077,981.5
非流动资产合计2,145,607,824.282,105,162,897.251,764,357,049.251,737,438,733.79
资产总计4,618,384,078.674,671,249,471.014,737,743,654.844,531,516,715.29
流动负债合计637,309,672.55758,252,066.9845,705,990.93725,283,757.57
非流动负债合计77,395,391.8375,340,080.38124,422,903.64156,821,565.43
负债合计714,705,064.38833,592,147.28970,128,894.57882,105,323
归属于母公司股东权益合计3,901,801,603.233,835,627,197.553,765,793,758.43,647,531,472.52
股东权益合计3,903,679,014.293,837,657,323.733,767,614,760.273,649,411,392.29
负债和股东权益合计4,618,384,078.674,671,249,471.014,737,743,654.844,531,516,715.29
现金流量表
报告期2024-03-312023-12-312023-09-302023-06-30
经营活动现金流入小计276,340,855.261,131,870,298.28910,354,099.44553,229,405.97
经营活动现金流出小计143,254,275.52593,836,368.39464,708,550.15331,765,669.62
经营活动产生的现金流量净额133,086,579.74538,033,929.89445,645,549.29221,463,736.35
投资活动现金流入小计446,189,764.612,043,866,185.89918,287,031.32529,467,209.98
投资活动现金流出小计220,764,662.942,372,862,356.981,103,959,733.45746,817,039.36
投资活动产生的现金流量净额225,425,101.67-328,996,171.09-185,672,702.13-217,349,829.38
筹资活动现金流入小计50,059,095.89344,118,858.75260,000,000165,000,000
筹资活动现金流出小计177,480,673.8446,544,220.24315,061,968.21208,180,146.78
筹资活动产生的现金流量净额-127,421,577.91-102,425,361.49-55,061,968.21-43,180,146.78
汇率变动对现金及现金等价物的影响0.0654,930.5--
现金及现金等价物净增加额231,090,103.56106,667,327.81204,910,878.95-39,066,239.81
期末现金及现金等价物余额788,458,886.5557,368,782.94655,612,334.08411,635,215.32
  主营收入+营业利润
 
  净利润+每股收益
  股东权益+未分配利润
 
  总资产+负债
  投资要点

    截至2024年第一季度实现净利润0.87亿元,每股收益0.18元。

    截至2024年第一季度最新股东权益390367.90万元,未分配利润202193.77万元。

    截至2024年第一季度最新总资产461838.41万元,负债71470.51万元。

利润表
报告期2024-03-312023-12-312023-09-302023-06-30
营业总收入204,929,240.41,064,074,588.89827,439,173.94531,839,356.71
营业总成本117,548,562.59547,826,665.17407,570,296.65263,731,462.07
营业利润100,624,673.5459,131,690.91412,743,443.37276,689,466.17
利润总额100,009,570.54457,580,664.5411,654,477.45275,005,589.86
净利润87,075,680.66395,580,552.7357,180,085.48238,976,717.5
其他综合收益3,322,297.4725,333,622.92--
综合收益总额90,397,978.13420,914,175.62357,180,085.48238,976,717.5
资产负债表
报告期2024-03-312023-12-312023-09-302023-06-30
流动资产合计2,472,776,254.392,566,086,573.762,973,386,605.592,794,077,981.5
非流动资产合计2,145,607,824.282,105,162,897.251,764,357,049.251,737,438,733.79
资产总计4,618,384,078.674,671,249,471.014,737,743,654.844,531,516,715.29
流动负债合计637,309,672.55758,252,066.9845,705,990.93725,283,757.57
非流动负债合计77,395,391.8375,340,080.38124,422,903.64156,821,565.43
负债合计714,705,064.38833,592,147.28970,128,894.57882,105,323
归属于母公司股东权益合计3,901,801,603.233,835,627,197.553,765,793,758.43,647,531,472.52
股东权益合计3,903,679,014.293,837,657,323.733,767,614,760.273,649,411,392.29
负债和股东权益合计4,618,384,078.674,671,249,471.014,737,743,654.844,531,516,715.29
现金流量表
报告期2024-03-312023-12-312023-09-302023-06-30
经营活动现金流入小计276,340,855.261,131,870,298.28910,354,099.44553,229,405.97
经营活动现金流出小计143,254,275.52593,836,368.39464,708,550.15331,765,669.62
经营活动产生的现金流量净额133,086,579.74538,033,929.89445,645,549.29221,463,736.35
投资活动现金流入小计446,189,764.612,043,866,185.89918,287,031.32529,467,209.98
投资活动现金流出小计220,764,662.942,372,862,356.981,103,959,733.45746,817,039.36
投资活动产生的现金流量净额225,425,101.67-328,996,171.09-185,672,702.13-217,349,829.38
筹资活动现金流入小计50,059,095.89344,118,858.75260,000,000165,000,000
筹资活动现金流出小计177,480,673.8446,544,220.24315,061,968.21208,180,146.78
筹资活动产生的现金流量净额-127,421,577.91-102,425,361.49-55,061,968.21-43,180,146.78
汇率变动对现金及现金等价物的影响0.0654,930.5--
现金及现金等价物净增加额231,090,103.56106,667,327.81204,910,878.95-39,066,239.81
期末现金及现金等价物余额788,458,886.5557,368,782.94655,612,334.08411,635,215.32
  十大流通股东
十大流通股东 报告期:2024-03-31
股东名称 持股数量(万股) 占总股本比例(%) 上期持股变化(万股)
武汉华中农大资产经营有限公司7800.4316.730.00
陈焕春7086.0515.200.00
金梅林3667.787.870.00
何启盖3317.337.120.00
吴美洲2858.626.130.00
叶长发2750.615.900.00
李广欣516.501.11516.50
华夏人寿保险股份有限公司293.600.630.00
  主力控盘
  公司简介
科前生物 所属地域: 湖北省 涉及概念: 禽流感,宠物经济,沪股通,融资融券,动物疫苗
主营业务: 一般项目:生物制品的开发、研制;动物传染病诊断咨询及技术服务;兽药生产、销售(凭许可证在核定期限内经营);货物进出口、技术进出口、代理进出口(不含国家禁止或限制进出口的货物或技术);实验分析仪器销售;专用化学产品销售(不含危险化学品)(除依法须经批准的项目外,凭营业执照依法自主开展经营活动)
上市日期: 2020-09-22 每股净资产: 8.37元 每股收益: 0.18元 净利润: 0.87亿元 净利润增长率: -35.64%
营业收入: 2.05亿元 每股现金流: 0.29元 每股公积金: 2.45元 每股未分配利润: 4.34元 总股本: 4.66亿 流通股: 4.66亿
以上信息为合作方、加盟公司及会员收集,本站不拥有版权,版权归原作者所有,所载文章、数据仅供参考,据此操作,风险自负。

中 华 顶 尖 财 经 -- 中 华 顶 尖 网 络 信 息 服 务 中 心